AVAX FILES IND FOR TRIAL OF LUNG CANCER DRUG

AVAX Technologies has filed an investigational new drug application with the FDA for a Phase I/II clinical trial treating patients with Stage I and II non-small cell lung cancer.

The study will utilize AVAX's AC vaccine therapeutic, which will be given as a first-line treatment after surgery. The study endpoints include safety and a measure of cellular immunity -- delayed-type hypersensitivity to the patient's own lung cancer cells.